Head-to-Head Comparison of the Efficacy and Safety of All Five Commercially Available Botulinum Neurotoxin Type A Products for the Treatment of Glabellar Rhytides: A Multicenter, Double-Blind, Randomized Controlled Trial
Latest Information Update: 25 Aug 2026
At a glance
- Drugs Botulinum Toxin A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
Most Recent Events
- 14 Aug 2026 Planned primary completion date changed from 1 Jan 2027 to 15 Jan 2027.
- 02 Jul 2026 Planned number of patients changed from 200 to 325.
- 02 Jul 2026 Planned End Date changed from 1 Nov 2025 to 1 Feb 2027.